Elevated blood pressure is a common, heritable cause of cardiovascular disease worldwide. To date, identification of common genetic variants influencing blood pressure has proven challenging. We tested 2.5 million genotyped and imputed SNPs for association with systolic and diastolic blood pressure in 34,433 subjects of European ancestry from the Global BPgen consortium and followed up findings with direct genotyping (N r 71,225 European ancestry, N r 12,889 Indian Asian ancestry) and in silico comparison (CHARGE consortium, N ¼ 29,136). We identified association between systolic or diastolic blood pressure and common variants in eight regions near the CYP17A1 (P ¼ 7 Â 10 À24 ),
The World Health Organization estimated that, in 2005, the annual death toll from cardiovascular disease reached 17.5 million worldwide [1] [2] [3] . Increases in systolic and diastolic blood pressure (SBP, DBP), even within the normal range, have a continuous and graded impact on cardiovascular disease risk and are major contributors in half of all cardiovascular deaths 2, 3 . Lifestyle influences, including dietary sodium intake, alcohol excess, elevated body mass index and lack of exercise, are known to increase blood pressure 4 . Studies of familial aggregation suggest that there is also a substantial heritable component to blood pressure 5 . Studies of rare mendelian disorders of hypertension and hypotension have produced the most notable progress toward understanding the heritable basis of blood pressure, showing that mutations in genes influencing renal salt handling can have a severe effect on blood pressure 6 . Detailed study of these genes has identified rare variants (minor allele frequency (MAF) o 0.1%) that influence blood pressure in the general population 7 and evolving evidence suggests a potential role for common variation in some of the same genes [8] [9] [10] .
The identification of common variants affecting blood pressure using genome-wide association studies (GWAS) has proven challenging, compared to the success of GWAS of other common complex disorders 11, 12 . However, meta-analysis of multiple studies with large total sample sizes has the potential to facilitate detection of variants with modest effects. We therefore formed the Global Blood Pressure Genetics (Global BPgen) consortium and conducted meta-analysis of GWAS in 34,433 individuals of European ancestry with SBP and DBP measurements (stage 1), followed by direct genotyping (stage 2a) and in silico (stage 2b) analyses ( Supplementary Fig. 1 online) . Our analyses identified eight loci showing genome-wide significant association with systolic or diastolic blood pressure, each of which was also associated with hypertension.
RESULTS

Genome-wide association for blood pressure
Global BPgen includes 17 cohorts of European ancestry ascertained through population-based sampling or case-control studies. In our primary analysis (stage 1), we examined individuals aged r70 years from 13 population-based studies and from control groups from four case-control studies ( Table 1) . Individuals treated for hypertension were imputed to have 15 mm Hg higher SBP and 10 mm Hg higher DBP than the observed measurements, as this has been shown to reduce bias and improve statistical power 13 . SBP and (separately) DBP measures were each adjusted for age, age 2 , body mass index and any study-specific geographic covariates within cohort-and sex-specific regression analyses. Genome-wide SNP genotyping was done on a variety of platforms and subjected to standard quality control measures (Methods and Supplementary Table 1 online). Genotypes for B2.5 million autosomal SNPs in the HapMap CEU sample were then imputed in each study and tested for association with SBP and DBP separately under an additive genetic model. Test statistics from association analysis of SBP and DBP from each cohort were adjusted using genomic control 14 to avoid inflation of results due to interindividual relatedness or residual population stratification, and to ensure good calibration of test statistics. Meta-analysis of results was carried out using inverse variance weights. Test statistic inflation postmeta-analysis was modest (l GC ¼ 1.08 SBP; l GC ¼ 1.07 DBP); genomic control correction was applied again. The plots of test statistics against expectations under the null suggest an excess of extreme values (cohort-specific and meta-analysis quantile-quantile plots are presented in Supplementary Fig. 2a online) .
On meta-analysis of results from 34,433 individuals in stage 1, we observed 11 independent signals with P o 10 À5 for SBP and 15 for DBP, with two results attaining P o 5 Â 10 À8 , corresponding to genome-wide significance when adjusting for the B1 million independent common variant tests estimated for samples of European ancestry ( Supplementary Fig. 2b ) 15 . Table 3 and Supplementary Fig. 2b ). Three of these loci overlap with genome-wide significant loci identified in the CHARGE analyses (10q24 for SBP and 12q24 and 15q24 for DBP).
For SBP, the strongest evidence for association was at 10q24 (rs11191548, MAF ¼ 0.09, 1.16 mm Hg higher per major allele, P ¼ 7 Â 10 À24 , Table 2 and Fig. 1b) . This SNP is part of a large cluster of associated SNPs spanning a B430-kb region at 10q24 showing association in our GWAS meta-analysis. The locus includes six genes, most notably CYP17A1, which encodes the cytochrome P450 enzyme CYP17A1 (also known as P450c17) that mediates steroid 17a-hydroxylase and 17,20-lyase activity. The first enzymatic action is a key step in the biosynthesis of mineralocorticoids and glucocorticoids that affect sodium handling in the kidney and the second is involved in sex-steroid biosynthesis. Missense mutations in CYP17A1 cause one form of adrenal hyperplasia characterized by hypertension, hypokalemia and reduced plasma renin activity 17, 18 . None of the five other genes or transcripts in the region (Fig. 1b) is an obvious candidate for blood pressure regulation.
The second locus associated with SBP was at 1p36 (rs17367504, MAF 0.14, 0.85 mm Hg lower SBP per minor allele, P ¼ 2 Â 10 À13 , Table 2 and Fig. 1a ). This SNP is located in an intron of the MTHFR (methylenetetrahydrofolate reductase) gene in a region with many plausible candidate genes, including MTHFR, CLCN6, NPPA, NPPB and AGTRAP. The strongest signal in the locus is 6.4 kb away from and uncorrelated with rs1801133 (C677T, A222V, r 2 CEU ¼ 0.06), a coding variant that has been related to higher plasma homocysteine concentration 19 , pre-eclampsia 20 , and variably hypertension 21 . In Global BPgen rs1801133 was associated with 0.08 mm Hg higher SBP per T allele (P ¼ 0.56), 0.24 mm Hg higher DBP (P ¼ 0.01) and an odds ratio for hypertension of 1.00 (95% CI ¼ 0.94-1.05, P ¼ 0.90).
The natriuretic peptides encoded by NPPA and NPPB, also located within the 1p36-associated interval, have vasodilatory and natriuretic properties and the NPPA knockout mouse has salt-sensitive hypertension 22 . A recent study found that the minor allele of rs5068 (43 kb from rs17367504, r 2 CEU ¼ 0.26), in the 3¢ untranslated region of NPPA, is associated with higher plasma atrial and B-type natriuretic peptide, as well as lower SBP, DBP and odds of hypertension 23 . In the Global BPgen stage 1 meta-analysis we replicated association of the minor allele of rs5068 with 0.97 mm Hg lower SBP (P ¼ 3 Â 10 À4 ), 0.60 mm Hg lower DBP (P ¼ 1 Â 10 À3 ) and 10% lower odds of hypertension (P ¼ 0.04). Whether the associations of rs5068 and rs17367504 reflect the same or different underlying signals remains to be established. The less wellcharacterized gene CLCN6, also at the 1p36 locus, encodes a neuronally expressed chloride channel that has not previously been implicated in blood pressure physiology, although rare mutations in other renally expressed chloride channels are associated with extremes of blood 24, 25 . Lastly, AGTRAP (encoding angiotensin II receptor-associated protein) negatively regulates angiotensin II signaling by interacting with the angiotensin II type 1 receptor, a critical component of the renin-angiotensin-aldosterone system 26 .
The third locus associated with SBP was at 17q21 (rs12946454, MAF 0.28, 0.57 mm Hg higher SBP per minor allele, P ¼ 1 Â 10 À8 , Table 2 and Fig. 1c ). This SNP is located in an intron in PLCD3 (phospholipase C-delta isoform), and is part of a cluster of associated SNPs. PLCD3 is a member of the phospholipase C family of enzymes, important in vascular smooth muscle signaling and activated by the vasoactive peptides angiotensin II and endothelin 27 .
The DBP SNP with the strongest association evidence on joint analysis is rs1378942 (MAF ¼ 0.36, 0.43 mm Hg higher per minor allele, P ¼ 1 Â 10 À23 , Table 2 and Fig. 1g ), which is in an intron Shown is the top SNP for each independent locus associated with systolic or diastolic blood pressure (P o 5 Â 10 À7 ) on joint analysis in up to 134,258 individuals of European ancestry from Global BPgen GWAS (stage 1), follow-up genotyping (stage 2a) and in silico exchange with the CHARGE consortium (stage 2b). The eight genome-wide significant loci (P o 5 Â 10 À8 ) are shown in boldface. For stage 1 and 2b results based on imputed genotypes, an effective sample size is estimated to be the sum of the cohort-specific products of the imputation quality metric and the sample size. The total sample size is the sum of the effective sample sizes and the direct genotyping sample size. Effect sizes are on the mm Hg scale for increasing copy of the coded (alphabetically higher) allele as estimated by the beta coefficient in linear regression. The proportion of variance explained by each SNP is shown (r 2 ). Meta-analysis was conducted using inverse variance weighting. Note that loci 10q21 and 15q24 show results for two SNPs selected for validation genotyping in an interim analysis (rs1530440, rs1378942) that were genome-wide significant on joint analysis of stage 1+2a+2b. These two SNPs are highly correlated with alternate SNPs at the locus (rs4590817, rs4886606, respectively) with slightly stronger significance in the final stage 1 meta-analysis. The originally selected SNPs are shown throughout the text for consistency.
of CSK at 15q24 and is one of a cluster of associated SNPs spanning B72 kb. Genes in the region include CYP1A2 (cytochrome P450 enzyme), CSK (c-src tyrosine kinase), LMAN1L (lectin mannosebinding1 like) and ARID3B (encoding AT-rich interacting domain protein). Other nearby genes include CYP1A1 (B60 kb) and CYP11A1 (B418 kb). Cytochrome P450 enzymes are responsible for drug and xenobiotic chemical metabolism in the liver and cellular metabolism of arachidonic acid derivatives 28 , some of which influence renal function, peripheral vascular tone and blood pressure. CYP1A2 is widely expressed, representing 15% of CYP450 enzymes produced in the liver and mediating the metabolism of multiple medications. A correlated SNP, rs762551 (MAF ¼ 0.31, r 2 ¼ 0.63, HapMap CEU) in an intron of CYP1A2 has been found to influence caffeine metabolism 29 . The ARID3B gene is embryonic lethal when knocked out in mouse, with branchial arch and vascular developmental abnormalities 30 , but is potentially interesting because of the presence of ARID5B at the 10q21 locus described below. The second DBP SNP is rs16998073 (MAF ¼ 0.21, 0.50 mm Hg higher per minor allele, P ¼ 1 Â 10 À21 , Table 2 and Fig. 1d ), which lies 3.4 kb upstream of FGF5 (fibroblast growth factor 5) on 4q21. The FGF5 protein is a member of the fibroblast growth factor (FGF) family that stimulates cell growth and proliferation in multiple cell types, including cardiac myocytes, and has been associated with angiogenesis in the heart 31 .
The third DBP SNP, rs653178 (MAF ¼ 0.47, 0.46 mm Hg lower DBP per major allele, P ¼ 3 Â 10 À18 , Table 2 and Fig. 1f ) at 12q24 is in an intron of the ATXN2 gene. This SNP is perfectly correlated with a missense SNP in exon 3 of SH2B3 (rs3184504, R262W). The minor allele of rs3184504, which is associated with higher DBP, has recently been associated with increased odds of type 1 diabetes 32 , celiac disease 33 , myocardial infarction, hypertension and higher eosinophil and other blood cell counts 34 . We did not find that other SNPs previously reported to be associated with type 1 diabetes, celiac disease or myocardial infarction were associated with blood pressure (data not shown). SH2B3 is expressed in hematopoietic precursor cells and in endothelial cells 35 . Murine knockout of the SH2B3 gene (also known as lymphocyte-specific adaptor protein, LNK) is associated with increased hematopoietic progenitors of several lineages 36 , suggesting that the minor allele of the missense SNP in humans results in a loss of SH2B3 function. In response to inflammatory stimuli, LNK seems to be a negative regulator of inflammatory signaling pathways in the endothelial cell, a cell type central to both blood pressure regulation and the process of atherosclerosis 35 .
Noticing that the minor T allele of rs3184504 associated with higher DBP is common in HapMap CEU (frequency 0.45) and absent in HapMap YRI, JPT and CHB samples, we sought evidence for recent positive selection. The derived T allele occurs on a long-range haplotype B1.5 Mb; relative to the haplotypes tagged by the ancestral allele, this is an unusual genomic feature (SNP-wise standardized integrated extended haplotype homozygosity [iHS] of À2.76, genebased empirical P value o0.006) 37 . In addition, measures of population differentiation provide evidence of a local selective sweep in HapMap CEU (Wright's F ST ¼ 0.26 for CEU-YRI comparison and 0.29 for CEU-JPT/CHB). Finally, an ascertainment-adjusted Fay and Wu's H statistic of À35.7 supports the presence of an excess of high frequency-derived alleles at the locus. In sum, these measures support the hypothesis that the minor (derived) allele rose quickly to intermediate frequency in European-derived populations, possibly owing to some selective advantage of immune response to infectious pathogens. Although enhancing SH2B3 activity might seem attractive to reduce risk for multiple diseases, the evidence for positive selection of an apparent loss-of-function allele and pleiotropic consequences suggest that enhancing SH2B3 activity could have unintended consequences.
The fourth DBP SNP, rs1530440 (MAF ¼ 0.19, 0.39 mm Hg lower per minor allele, P ¼ 1 Â 10 À9 , Table 2 and Fig. 1e ) at 10q21 is intronic and one of a cluster of SNPs in C10orf107, an open reading frame of unknown function. Nearby genes include ARID5B (A-rich interactive domain 5B (MRF1 like)), TMEM26 (transmembrane protein 26), RTKN2 (RhoA GTPase effector, rhotekin-2) and RHOBTB1 (RhoBTB GTPase). The Rho family of GTPases converts guanine triphosphate to inactive guanine diphosphate. The actions relating to other GTP-modulating enzymes may modulate salt-sensitive hypertension 38, 39 . The ARID5B gene is a member of the AT-rich interaction domain family of transcription factors and is highly expressed in cardiovascular tissue and involved in smooth muscle cell differentiation 40 .
The fifth DBP SNP, rs16948048 (MAF 0.39, 0.34 mm Hg higher DBP per minor allele, P ¼ 5 Â 10 À9 , Table 2 and Fig. 1h ) at 17q21 is upstream of ZNF652 (zinc finger protein 652) and PHB (prohibitin). Neither gene has previously been implicated in hypertension or other cardiovascular phenotypes.
We observed no significant interaction between the eight genomewide significant SNPs and sex (P 4 0.01, Supplementary Table 4 online). There was also no evidence of heterogeneity of effect across the samples examined for the eight SNPs (Q-statistic P 4 0.05).
Although we describe here promising candidates at each locus identified, the causal gene could be any of the genes around the association signal in each locus (Fig. 1) . Fine mapping and resequencing will be required to refine each association signal and to identify likely causal genetic variants that could be studied further in humans and in animal models. For each of eight SNPs, the upper row shows association statistics for the blood pressure trait used for the analysis in which they were selected (SBP or DBP). The lower row (in boldface) shows the equivalent association statistics for the alternate blood pressure trait. Results are shown for the 34,433 individuals in the stage 1 Global BPgen GWAS samples. Table 2 .
All variants are related to both blood pressure traits It remains to be clarified whether SBP or DBP is the better target for genetic investigation of blood pressure. The two traits are correlated and heritable, and both show strong increases with age, with DBP starting to plateau and in some individuals fall at ages above 60-65 years. Some have advocated the study of pulse pressure (SBP -DBP), which increases with advancing age, and is correlated positively with SBP and negatively with DBP and also shows evidence of heritability. In our GWAS and follow-up, we chose a priori to consider SBP and DBP as separate traits. Thus, validation was only attempted for either SBP or DBP, according to the trait for which the stage 1 P value was lowest. Because SBP and DBP are correlated (r B 0.50-0.70), it is perhaps not surprising to see that all eight genome-wide significant SNPs are associated with both SBP and DBP with the same directions of effect ( Table 3 and Fig. 2) . Thus, our presentation of results as SBP-or DBP-associated is somewhat arbitrary. The observation that each SNP shows stronger association with one trait or the other (typically by 1-2 orders of magnitude) could reflect sampling variation, small effect sizes or true differences in the underlying biologic basis of one trait or the other. A study designed to examine pulse pressure would be expected to show weaker (if any) association signals for the variants identified, which all showed concordant effects on SBP and DBP.
All variants are related to hypertension
We did not carry out a global GWAS of hypertension, which is expected to be underpowered to detect common variants of modest incremental effects on continuous blood pressure. For the eight SNPs that were genome-wide significant in continuous trait analysis, we examined the association with hypertension (SBP Z 140 mm Hg or DBP Z 90 mm Hg or antihypertensive medication use) compared to normotension (SBP r 120 mm Hg and DBP r 85 mm Hg and no antihypertensive medication use) in planned secondary analyses (N range ¼ 57,410-99,802). All alleles associated with continuous blood pressure were also associated with odds of hypertension in directions consistent with the continuous trait effect ( Table 4 and Fig. 2 ). The relative yields of the two approaches remain to be fully evaluated and will only become clearer upon completion of large ongoing GWA studies of dichotomous hypertension case-control collections. However, we examined the hypertension association of each of the eight SNPs genome-wide significantly associated with continuous SBP or DBP in the stage 1+2 meta-analysis. In the stage 1 Global BPgen samples alone, four of the eight SNPs had 0.01 o P r 0.10. These SNPs would not have been selected for follow-up genotyping had these tests been conducted as part of a hypertension GWAS. Thus, the study of continuous blood pressure allowed us to identify effects on risk of hypertension that would not have been readily discovered in a GWAS of hypertension drawn from these samples.
Extension to non-European samples
To date, the majority of complex disease association signals reaching genome-wide significance have been concentrated in populations of European ancestry, and it remains unclear whether these findings will transfer to individuals with other genetic backgrounds. We genotyped all stage 2a SNPs (four of which were not confirmed in the European ancestry analyses) in a separate Indian Asian sample of up to 12,889 individuals. We replicated the association of the SNP at 4q21 near Table 2 ) and the SNP at 10q24 near CYP17A1 (rs11191548, P ¼ 0.008, Supplementary Table 2 ). We did not replicate association of the SNP rs1378942 at CYP1A2 (P ¼ 0.17, same direction), which could reflect limited power to detect the modest effect size, differences in linkage disequilibrium patterns in Indian Asians compared to Europeans, or simply lack of association in individuals of Indian Asian ancestry. The marked allele frequency differences between the European samples (C allele frequency B0.35), the Indian Asian samples (0.77) and HapMap YRI (1.00) suggest distinct patterns of genetic variation at this locus across populations. A signal of positive selection has been suggested at the locus 37 , raising the potential functional importance of genetic variation in the region.
DISCUSSION
The eight loci described here and the additional loci reported by our colleagues in the CHARGE consortium are among the first confirmed associations between common genetic variants and blood pressure. Each association explains only a very small proportion of the total variation in SBP or DBP (B0.05-0.10%, approximately 1 mm Hg per allele SBP or 0.5 mm Hg per allele DBP, Table 2 ). However, the variants identified here have an aggregate effect on blood pressure, acting throughout the range of values (not just hypertensive), which has been shown to produce meaningful population changes in cardiovascular and stroke risk. For example, 2 mm Hg lower SBP, across the range of observed values, has been estimated to translate into 6% less stroke and 5% less coronary heart disease 2, 41 . Given the modest effects observed here and the limited power of this study to detect such effects, it is likely that many more common variants exist with weak effects upon blood pressure. This study illustrates the value of well-powered meta-analysis and follow-up Shown are the results for the top SNP from each genome-wide significant SBP or DBP locus from a logistic regression analysis of the odds of hypertension compared to normotension (see Methods). For comparison, the effect of the coded allele on the continuous blood pressure trait is shown. The inverse-variance-weighted meta-analysis results are shown. BP, blood pressure; OR, odds ratio.
genotyping, accompanied by in silico analysis, to establish definitively the relationship of these loci with blood pressure regulation in the general population. In a companion paper, the CHARGE consortium reports as genome-wide significant three of the eight loci that reached genome-wide significance in our Global BPgen joint analysis of stages 1 and 2. CHARGE also reports common variants at five additional genome-wide significant loci at 11p15 (Global BPgen P ¼ 0.009), 3p22 (P ¼ 0.01), 12q21 (P ¼ 0.008), 12q24 (P ¼ 0.05), and 10p12 (P ¼ 0.004, see companion CHARGE paper) 16 . Although these SNPs were not among our top ten SNPs for either blood pressure trait, the Global BPgen results from in silico exchange and for the same alleles are clearly consistent with the conclusions of the CHARGE investigators. Among the ten SBP and ten DBP loci at the top of the Global BPgen results, five loci were represented in the CHARGE top ten results (Supplementary Table 3 ). With the modest effect sizes we observed, it is not surprising that the top ten loci for each blood pressure trait would show only partial overlap.
We acknowledge that some limitations apply to our study. The participants in the individual studies comprising Global BPgen and our follow-up cohorts were ascertained using diverse criteria, had their blood pressure measured in a variety of ways and showed a broad range of age and treatment profiles. Even small differences in these factors could reduce power to detect the association of genetic variants with modest effect, although such heterogeneity should not increase the false-positive rate. Even though SBP and DBP are dynamic phenotypes resulting from multiple competing influences, estimates of the test-retest reliability of blood pressure measurements are approximately 0.65-0.75 in studies focused on blood pressure 2, 42, 43 . Moreover, a graded relationship between blood pressure measures and cardiovascular risk has been consistently observed, despite variability in blood pressure measures 2 . At the individual level, genetically determined alteration of 1 mm Hg SBP or 0.5 mm Hg DBP would be difficult to detect in the clinic, but large sample sizes use group-level differences in means to detect small genetic effects.
We chose a priori to adjust for body mass index (BMI), which explains B6-8% of the total variation in SBP and DBP, with the goal of reducing potential nongenetic contributions to blood pressure variability. Genetic variants could influence blood pressure acting through BMI as an intermediate, but such variants are best identified through BMI GWA studies such as those recently reported by Loos et al. 44 and Willer et al. 45 .
Exposures such as dietary sodium and potassium intake or excessive alcohol use also contribute to interindividual differences in blood pressure. These were measured in a minority of our samples and thus we could not meaningfully adjust for them in our study. Under the assumption that these do not alter blood pressure systematically by genotype, we would expect this omission to reduce power only slightly.
We adjusted for use of antihypertensive therapy by adding 15 mm Hg and 10 mm Hg to SBP and DBP, respectively. This approach has been shown to be superior to ignoring antihypertensive treatment or to excluding individuals on therapy 13 . However, it is clear that factors such as medication number and dosage and variation in prescription patterns in different countries and time periods make this adjustment scheme an oversimplification. Again, such effects should generally bias our findings toward the null.
There are many classes of widely used therapies with strong antihypertensive effects. We examined the association of common variants at the loci extending 100 kb on either side of the genes encoding the targets for thiazide diuretics (SLC12A3), loop diuretics (SLC12A1), ACE inhibitors (ACE), angiotensin II receptor type 1 blockers (AGTR1), beta adrenoreceptor blockers (ADRB1, ADRB2), alpha adrenoreceptor antagonists (ADRA1A, ADRA1B, ADRA1D), calcium channel blockers (CACNA1S, CACNA1C, CACNA1D, CAC-NA1F) and aldosterone antagonists (CYP11B2). No results exceeded chance expectations. This does not exclude the existence of variants of weaker effects or variants that were missed because they were not covered by existing arrays.
Moreover, the strength of association of variation in a gene with a trait (or lack thereof) says nothing about the potential strength of a drug designed to agonize or antagonize the product of that gene. For example, a common variant in HMGCR has only a modest effect on fasting lipids 46 , yet statin therapy, which inhibits the HMGCR enzyme to lower LDL cholesterol, substantially lowers risk of cardiovascular disease. Thus, the implication of modest common variant genetic effects is not just a function of the ability to identify tendency toward higher or lower blood pressure in carriers of alternate alleles, but also the ability to recognize relevant targets for therapy that have defined in vivo relevance in humans.
Although targeted pharmacotherapy has theoretical appeal, clinical trials to demonstrate the utility and cost-effectiveness of such approaches will be required before such personalized medicine can be endorsed. The association signals identified here will need to be refined through fine mapping, and resequencing will be needed to define more fully the allelic spectrum of variants at each locus that contributes to interindividual differences in blood pressure. Our findings offer initial insights into the genetic basis of a problem of global proportions and the potential for an improved understanding of blood pressure regulation. These loci may point to new targets for blood pressure reduction and ultimately additional opportunities to prevent the growing public health burden of cardiovascular disease.
METHODS
Overall study design. An expanded description of the methods is provided in the Supplementary Methods online. The study comprised two-staged analyses carried out separately for SBP and DBP. Stage 1 was a meta-analysis of directly genotyped and imputed SNPs from individuals of European descent in 17 samples drawn from population-based or control samples in case-control studies in the Global BPgen consortium. In stage 2a, we selected 12 SNPs for genotyping in up to 71,225 individuals of European descent from 13 studies and up to 12,889 individuals of Indian Asian ancestry from one study. In stage 2b, we selected 20 SNPs (10 SBP, 10 DBP) for in silico analysis in 29,136 individuals of European descent from the CHARGE consortium (stage 2b, see Supplementary Fig. 1 Imputation. Imputation of allele dosage of ungenotyped SNPs in HapMap CEU v21a or v22 was carried out using MACH 47 or IMPUTE 48 with parameters and preimputation filters as specified in Supplementary Table 1 . SNPs were excluded from analysis if the cohort-specific imputation quality as assessed by r2.hat (MACH) or .info (IMPUTE) metrics was o0.30. In total, up to 2,497,993 genotyped or imputed autosomal SNPs were analyzed.
Phenotype modeling. In individuals taking antihypertensive therapies, blood pressure was imputed by adding 15 mm Hg and 10 mm Hg for SBP and DBP, respectively 13 . Continuous SBP and DBP were adjusted for age, age 2 , body mass index and any study-specific geographic covariates in sex-specific linear regression models. In FUSION and SardiNIA, which included family-based samples, sex-pooled linear regression was carried out with the addition of sex as a covariate. Residuals on the mm Hg scale were used as univariate traits in genotype-phenotype analysis.
In secondary analyses, hypertension was defined by the presence of SBP Z140 mm Hg or diastolic blood pressure Z90 mm Hg or self-report of taking a medication for the treatment of hypertension. Normotensive controls were defined as individuals not taking any antihypertensives and having a SBP r120 mm Hg and a DBP r85 mm Hg.
Genotype-phenotype association analysis. Genotype-phenotype association of SBP and DBP residuals was carried out under an additive model using software as specified in Supplementary Table 1 . Analysis of hypertension for eight genome-wide significant continuous blood pressure loci was done using logistic regression to adjust for age, age 2 , sex and body mass index.
Meta-analysis of stage 1 samples. All cohort-specific effect estimates and coded alleles were oriented to the forward strand of the NCBI35 reference sequence of the human genome, using the alphabetically higher allele as the coded allele. For example, for a G/T SNP coded GG ¼ 0, GT ¼ 1, TT ¼ 2, the coded allele would be T. To capture the power loss due to imperfect imputation, we estimated 'N effective' , which was the sum of the cohort-specific products of the imputation quality metric and the sample size. No filtering on minor allele frequency was used. Genomic control 14 was carried out on cohort-and sexspecific test statistics. Lambda estimates are given in Supplementary Table 1 ; quantile-quantile plots are shown in Supplementary Figure 2a . Meta-analysis in stage 1 was conducted using inverse variance weights. Stage 1 meta-analysis results were subject to genomic control.
Selection of SNPs for stage 2. Twelve SNPs were selected for follow-up in stage 2a from among the results with P o 10 À5 during interim analyses. For in silico exchange with the CHARGE consortium (stage 2b), we identified the top independent loci to select ten SBP and ten DBP SNPs. If a SNP in one top ten list was also among the top ten for the alternate blood pressure trait, we kept the locus with the lower P value and went to the next locus on the list for the alternate blood pressure trait. Because a SNP at the 3q26 locus (MDS1) was selected in an interim analysis for direct genotyping, it was retained as the tenth locus for DBP even though its significance was reduced in the final stage 1 DBP GWAS analysis. Pooled analysis of first and second stage samples. Meta-analysis of stage 1, 2a and 2b results was conducted using inverse variance weighting. Standard errors were multiplied by the square root of the lambda estimate for genomic control and are presented throughout the text. Nominal P values after genomic control 14 are presented. We considered associations genome-wide significant if they exceeded P ¼ 5 Â 10 À8 , a Bonferroni correction for the estimated 1 million independent common variant tests in the human genome of European-derived individuals 14, 15 .
Note: Supplementary information is available on the Nature Genetics website.
